Back to search
Immune-related Adverse Event
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Immune-related Adverse Event trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Immune-related Adverse Event trials you may qualify forDuring the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psyc…
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers. Imm…
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for…
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying rese…
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver i…
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treat…
This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associa…
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.